Pharmacological Research, Journal Year: 2019, Volume and Issue: 152, P. 104617 - 104617
Published: Dec. 24, 2019
Language: Английский
Toxins, Journal Year: 2022, Volume and Issue: 14(10), P. 648 - 648
Published: Sept. 20, 2022
The gut microbiota consists of trillions microorganisms, fulfilling important roles in metabolism, nutritional intake, physiology and maturation the immune system, but also aiding abetting progression chronic kidney disease (CKD). human microbiome bacterial species from five major phyla, namely Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, Verrucomicrobia. Alterations members these phyla alter total microbiota, with a decline number symbiotic flora an increase pathogenic bacteria, causing or aggravating CKD. In addition, CKD-associated alteration this intestinal results metabolic changes accumulation amines, indoles phenols, among other uremic metabolites, which have feedforward adverse effect on CKD patients, inhibiting renal functions increasing comorbidities such as atherosclerosis cardiovascular diseases (CVD). A classification toxins according to degree known toxicity based experimental evidence their (number systems affected) overall clinical was selected identify representative small water-soluble compounds, protein-bound compounds middle molecules relation summarized. Gut-derived metabolites accumulating patients further exhibit cell-damaging properties, damage epithelial cell wall, permeability lead translocation bacteria endotoxins into circulatory system. Elevated levels endotoxemia inflammation, accelerating progression. recent years, role pathophysiology has emerged aspect corrective treatment; however, mechanisms by contributes are still not completely understood. Therefore, review summarizes current state research regarding alterations microbiome, toxin production, barrier degradation.
Language: Английский
Citations
42
Nature Reviews Nephrology, Journal Year: 2023, Volume and Issue: 19(10), P. 646 - 657
Published: July 24, 2023
Language: Английский
Citations
29
Immunity, Journal Year: 2024, Volume and Issue: 57(6), P. 1306 - 1323.e8
Published: May 29, 2024
Language: Английский
Citations
17
Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15
Published: March 8, 2024
Objective Emerging evidence has provided compelling linking gut microbiota (GM) and diabetic nephropathy (DN) via the “gut-kidney” axis. But causal relationship between them hasn’t been clarified yet. We perform a Two-Sample Mendelian randomization (MR) analysis to reveal connection with GM development of DN, type 1 diabetes (T1DN), 2 (T2DN), mellitus (T1DM), (T2DM). Methods used summary data from MiBioGen on 211 taxa in 18340 participants. Generalized MR methods were conducted estimate their causality risk T1DN, T2DN, T1DM T2DM FinnGen. To ensure reliability findings, comprehensive set sensitivity analyses confirm resilience consistency results. Results It was showed that Class Verrucomicrobiae [odds ratio (OR) =1.5651, 95%CI:1.1810-2.0742, P FDR=0.0018], Order Verrucomicrobiales (OR=1.5651, 95%CI: 1.1810-2.0742, FDR=0.0018) Family Verrucomicrobiaceae (OR=1.3956, 95%CI:1.0336-1.8844, FDR=0.0296) had significant DN. Our found associations including Verrucomimicrobiae (OR=1.8227, 95% CI: 1.2414-2.6763, PFDR=0.0139), 1.8227-2.6764, PFDR=0.0024), Rhodospirillales (OR=1.8226, 1.2412-2.6763, PFDR=0.0026), Verrucomicroniaceae PFDR=0.0083). The Eubacteriumprotogenes (OR=0.4076, 0.2415-0.6882, PFDR=0.0021) exhibited protection against T1DN. Sensitivity confirmed there no heterogeneity pleiotropy. Conclusions At gene prediction level, we identified specific is causally linked DN both patients. Moreover, distinct microbial changes T1DN differed those seen offering valuable insights into signatures associated subtype nephropathy.
Language: Английский
Citations
11
Pharmacological Research, Journal Year: 2019, Volume and Issue: 152, P. 104617 - 104617
Published: Dec. 24, 2019
Language: Английский
Citations
75